Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat

British Journal of Pharmacology

Volumn 149, Issue 6, 2006, Pages 647-656

  Finberg, J P M ^a   Gross, A ^b   Bar Am, O ^a   Friedman, R ^b   Loboda, Y ^a   Youdim, M B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

Blood pressure; Carbidopa; Clorgyline; Heart rate; L DOPA; Rasagiline; Selegiline; Tranylcypromine

Indexed keywords

CARBIDOPA; CATECHOLAMINE; CLORGYLINE; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; RASAGILINE; SELEGILINE; TRANYLCYPROMINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR SYSTEM; CATECHOLAMINE RELEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; HEART RATE; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD PRESSURE; HEART RATE; LEVODOPA; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33751019439     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706908     Document Type: Article

References (39)

1. Abassi ZA, Binah O, Youdim MBH (2004). Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol 143: 371-378.
2. Bexis S, Docherty JR (2006). Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve α-adrenoceptors. Br J Pharmacol 147: 926-934.
3. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975). The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 35: 303-326.
4. Calne DB, Brennan J, Spiers ASD, Stern GM (1970). Hypotension caused by L-Dopa. BMJ 1: 474-475.
5. Chen JC, Swope DM (2005). Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878-894.
6. Churchyard A, Mathias CJ, Lees AJ (1997). Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiat 63: 228-234.
7. Churchyard A, Mathias CJ, Lees AJ (1999). Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Movement Disord 14: 246-251.
8. Dayan L, Finberg JPM (2003). L-DOPA increases noradrenaline turnover in central and peripheral nervous systems. Neuropharmacology 45: 524-533.
9. Drieman JC, Van Kan FJPM, Thijssen HHW, Van Essen H, Smits JFM, Struijker Doudier HAJ (1994). Regional haemodynamic effects of dopamine and its prodrugs L-dopa and gludopa in the rat and in the glycerol-treated rat as a model for acute renal failure. Br J Pharmacol 111: 1117-1122.
10. Finberg JPM, Sabbagh A, Youdim MBH (1980a). Pharmacology of selective propargyl 'suicide' inhibitors of monoamine oxidase. In: Usdin TL, Sourkes E, Youdim MBH (eds). Enzymes and Neurotransmitters in Mental Disease. Wiley: London, pp 205-219.
11. Finberg JPM, Tenne M, Youdim MBH (1980b). Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MBH, Paykel ES (eds). Monoamine Oxidase Inhibitors - The State of the Art. Wiley: London, pp 31-43.
12. Finberg JPM, Youdim MBH (2002). Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43: 1110-1118.
13. Gill Jr JR, Masson DT, Bartter FC (1967). Effects of hydroxyamphetamine on the function of the sympathetic nervous system in normotensive subjects. J Pharmacol Exp Ther 155: 288-295.
14. Goldberg LI, Kohli JD (1983). Peripheral dopamine receptors: a classification based on potency series and peripheral antagonism. Trends Pharmacol Sci 2: 64.
15. Goldberg LI, Rajfer SI (1985). Dopamine receptors: applications in clinical cardiology. Circulation 722: 245-248.
16. Goldstein DS, Holmes C, Li ST, Bruce S, Metmen LV, Cannon III RO (2000). Cardiac sympathetic denervation in Parkinson's disease. Ann Intern Med 13: 338-347.
17. Henning M, Rubenson A (1970). Central hypotensive effect of L-3, 4-dihydroxyphenylalanine in the rat. J Pharm Pharmacol 22: 553-560.
18. Henning M, Rubenson A, Trolin G (1972). On the localization of the hypotensive effect of l-dopa. J Pharm Pharmacol 24: 447-451.
19. Hunter KR, Boakes AJ, Laurence DR, Stern GM (1970). Monoamine oxidase inhibitors and L-dopa. BMJ 719: 388.
20. Jarrott B, Iversen LL (1971). Noradrenaline metabolizing enzymes in normal and sympathetically denervated vas deferens. J Neurochem 18: 1-6.
21. Knoll J (1998). (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82: 57-66.
22. Knoll J, Magyar K (1972). Some puzzling effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds). Monoamine Oxidase: New Vistas, Adv Biochem Psychopharmacol Vol. 5, Raven Press: New York, pp 393-408.
23. Knoll J, Miklya I, Knoll B, Marko R, Kelemen K (1996). (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP] act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci 58: 817-827.
24. Kobayashi Y, Cavallotti D, Ricci A, Amenta F (1994). Localisation of dopamine D2-like receptors in pulmonary artery of the human and rabbit but not of the rat. Eur J Pharmacol 261: 229-236.
25. Laine K, Anttila M, Huuponen R, Maki-Ikola O, Heinonen E (2000). Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 23: 22-27.
26. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971). Physiologic, subjective and behavioural effects of amphetamine, metamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12: 245-260.
27. Medvedev OS, Esler M, Angus JA, Cox HS, Eisenhofer G (1990). Simultaneous determination of plasma noradrenaline and adrenaline kinetics: responses to nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia in the rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 341: 192-199.
28. Melamed E, Hefti F, Wurtman RJ (1980). Nonaminergic striatal neurons convert exogenous L-DOPA to dopamine in Parkinsonism. Ann Neurol 8: 558-563.
29. Misu Y, Goshima Y (1993). Is L-DOPA an endogenous neurotransmitter? Trends Pharmacol Sci 14: 119-123.
30. Montastruc JL, Chaumerliac C, Desboeuf K, Manika M, Bagheri H, Rascol O et al. (2000). Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol 23: 271-275.
31. Nichols AJ, Ruffolo RR (1987). Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparion with epinine and dopamine. J Pharmacol Exp Ther 242: 455-463.
32. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978). Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542-545.
33. Simpson LL (1978). Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol 27: 1591-1595.
34. Strolin-Benedetti M, Sanson G, Bona L, Gallina M, Persiani S, Tipton KF (1989). The oxidation of dopamine and epinine by the two forms of monoamine oxidase from rat liver. J Neural Transm 52 (Suppl): 233-238.
35. Stryjer R, Klein C, Treves TA, Rabey JM (2005). The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients. Acta Neurol Scand 111: 89-94.
36. Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllyla VV (1997). Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Neurology 48: 662-667.
37. Yamori Y, De Jong W, Yamabe H, Lovenberg W, Sjoerdsma A (1972). Effects of l-dopa and inhibitors of decarboxylase and monoamine oxidase on brain noradrenaline levels and blood pressure in spontaneously hypertensive rats. J Pharm Pharmacol 24: 690-695.
38. Youdim MBH, Gross A, Finberg JPM (2001). Rasagiline[N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500-506.
39. Zanzottera D, Ferlenga P, Marchini F, Semeraro C (1998). Pharmacological evidence for the presence of a peripheral postjunctional D2-like dopamine receptor in rabbit splenic artery. Brit J Pharmacol 123: 730-736.